Diabetic Macular Edema / Diabetic Retinopathy – Unmet Need – Unmet Need – Diabetic Macular Edema (US/EU)
Diabetic macular edema (DME) is caused by diabetes and is characterized by leaking fluid from abnormal blood vessels in the eye; this fluid can lead to swelling of the macula and visual impairment. Intravitreal vascular endothelial growth factor (VEGF) inhibitors, such as Regeneron / Bayer’s Eylea, Roche / Novartis’s Lucentis, and Roche’s Avastin, are the most common pharmacotherapies for treating DME, owing to their proven efficacy and safety. AbbVie’s Ozurdex and Alimera Sciences’ Iluvien, two long-acting corticosteroid implants, are also used to treat DME. However, these drugs all have clinical shortcomings in terms of efficacy, safety, and/or delivery, creating opportunities for new and improved alternatives. Our content examines the key treatment drivers and analyzes the greatest areas of unmet need, thereby presenting the opportunities in this space.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for DME?
- What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for DME?
- What are the prevailing areas of unmet need and opportunity in DME?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European ophthalmologists for a hypothetical new DME drug?
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in March 2022
Key companies: Roche, Regeneron, Novartis, Bayer, AbbVie, Alimera Sciences
Key drugs: Eylea, Lucentis, Avastin, Ozurdex, Iluvien
Table of contents
- Diabetic Macular Edema / Diabetic Retinopathy - Unmet Need - Unmet Need - Diabetic Macular Edema (US/EU)
- Unmet need - DME - TPP simulator - June 2022
- Executive summary
- Introduction
- Treatment drivers and goals
- Key findings: attribute importance
- Relative importance of efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to surveyed ophthalmologists' prescribing decisions in DME
- Importance of efficacy attributes to prescribing decisions in DME: United States
- Importance of efficacy attributes to prescribing decisions in DME: Europe
- Importance of safety and tolerability attributes to prescribing decisions in DME: United States
- Importance of safety and tolerability attributes to prescribing decisions in DME: Europe
- Importance of convenience of administration attributes to prescribing decisions in DME: United States
- Importance of convenience of administration attributes to prescribing decisions in DME: Europe
- Importance of nonclinical factors to prescribing decisions in DME: United States
- Importance of nonclinical factors to prescribing decisions in DME: Europe
- Key findings: stated vs. derived importance
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in DME: United States
- Stated vs. derived importance of key efficacy, safety and tolerability, convenience of administration, and nonclinical attributes to prescribing decisions in DME: Europe
- Product performance against treatment drivers and goals
- Key findings
- Overall performance of key therapies for DME: United States
- Overall performance of key therapies for DME: Europe
- Mean overall performance of key therapies for DME: United States and Europe
- Relative performance of key therapies for DME across select efficacy attributes: United States
- Relative performance of key therapies for DME across select efficacy attributes: Europe
- Relative performance of key therapies for DME across select safety and tolerability attributes: United States
- Relative performance of key therapies for DME across select safety and tolerability attributes: Europe
- Relative performance of key therapies for DME across select convenience of administration attributes: United States
- Relative performance of key therapies for DME across select convenience of administration attributes: Europe
- Relative performance of key therapies for DME across select nonclinical attributes: United States
- Relative performance of key therapies for DME across select nonclinical attributes: Europe
- Assessment of unmet need
- Key findings: unmet need in DME
- Surveyed ophthalmologistsu2019 satisfaction with the performance of key therapies for DME on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: United States
- Surveyed ophthalmologistsu2019 satisfaction with the performance of key therapies for DME on efficacy, safety and tolerability, convenience of administration, and nonclinical factors: Europe
- Surveyed ophthalmologists' ascribed level of unmet need across key efficacy attributes in DME: United States
- Surveyed ophthalmologists' ascribed level of unmet need across key efficacy attributes in DME: Europe
- Surveyed ophthalmologists' ascribed level of unmet need across key safety and tolerability attributes in DME: United States
- Surveyed ophthalmologists' ascribed level of unmet need across key safety and tolerability attributes in DME: Europe
- Surveyed ophthalmologists' ascribed level of unmet need across key convenience of administration attributes in DME: United States
- Surveyed ophthalmologists' ascribed level of unmet need across key convenience of administration attributes in DME: Europe
- Surveyed ophthalmologists' ascribed level of unmet need across key nonclinical factors in DME: United States
- Surveyed ophthalmologists' ascribed level of unmet need across key nonclinical factors in DME: Europe
- Key findings: unmet need in DME and related indications
- Surveyed ophthalmologists' ascribed level of unmet need in DME and related indications: United States
- Surveyed ophthalmologists' ascribed level of unmet need in DME and related indications: Europe
- Opportunity analysis
- Target product profiles
- Appendix
Related Market Assessment Reports
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems. SLE symptoms range from general malaise to serious CNS and renal manifestations. Hydroxychloroquine…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Atopic Dermatitis (US)
AD is a chronic inflammatory skin disorder characterized by relapsing dry, red, and itchy skin. AD typically develops in early childhood and can persist into adulthood. Topical immunotherapy is the…
Report
Acute Coronary Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – Acute Coronary Syndrome: Secondary Prevention (US)
Acute coronary syndrome (ACS)—a subtype of coronary artery disease—is an umbrella term encompassing ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, and unstable…
